GRI Bio, Inc.

NasdaqCM:GRI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 3.07 M

Share Price

USD 1.31

Avg Daily Volume

497,880

Change (1 day)

-0.76%

Change (1 year)

Change (YTD)

-85.73%

GRI Bio, Inc. Enterprise Value to EBITDA (EV/EBITDA) on June 23, 2025

GRI Bio, Inc. Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

GRI Bio, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
GRI Bio, Inc. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 23, 2025, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
GRI Bio, Inc. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

NasdaqCM: GRI

GRI Bio, Inc.

CEO	Dr. W. Marc Hertz Ph.D.
IPO Date	Feb. 10, 2021
Location	United States
Headquarters	2223 Avenida de la Playa
Employees	3
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.